The following is a guest post by Dassault Systèmes’ Adrian Stevens, Senior Manager of Modeling & Simulations and Tim Moran, Director of Product Marketing, Biologics. To view the exclusive webinar “A closer look at Dassault Systemès Designed to Cure Industry Solutions Experience,” click here. When you’re inside a maze, it’s difficult to […]
Current regulatory guidelines for the pharmaceutical industry are growing more stringent than ever, with strict adherence to quality standards taking top priority. Furthermore, the increased scrutiny shows no signs of lessening anytime soon. In recent years, the FDA has trended toward issuing more warning letters to life sciences facilities and […]
Major depressive disorder, or simply depression as it’s often referred colloquially, is one of the most common forms of mental illness today. Due to the number of people afflicted, many pharmaceutical companies have dedicated a large amount of resources to develop medications that can treat and manage the mood disorder. In fact, there are over 20 types of antidepressants currently available on the market. Despite the variety of approved medications, many people with depression—especially those with the chronic form of the disorder—continue without relief as existing drugs fail to help their condition. As a result, some patients have turned toward alternative methods such as repeated exposure to near-infrared light and infusions of a staple anesthetic popular among veterinarians and burn centers. And while the latter treatment, in particular, has caused some excitement within the psychiatric community due to its fast-acting effects and high efficacy among patients, the fact is that its results are only temporary. Patients can relapse only one week after an infusion. Such a treatment may function well as a stopgap in cases of people with serious symptoms of depression, but we cannot consider this viable in the long-term. The costs and dosing schedule necessary to administer the infusions could be untenable to the patient.
As Pharmaceutical/Biotech (Bio-Pharma) companies look for opportunities to accelerate innovation, continuous improvement is a strategic imperative. To fast-track innovation, companies need to be open to new ideas and have awareness of new and emerging systems and technologies.
Does your organization have the capacity for global expansion? As biotech and pharmaceutical companies pursue opportunity in maturing markets and emerging economies, they rely on commercial solutions to globally expand what has become an evolving vendor ecosystem. But opportunity has its price. Increasing the use of external resources to achieve clinical advancements and healthcare discoveries requires the best practices for managing the complexities of R&D and therapeutic innovation. Enterprises within the life sciences industries looking to squeeze the most out of their investments as they expand into new markets face the ultimate challenge: improve operational excellence to better deliver new therapies while minimizing and regulatory risk and cost.
As an industry actively transforming itself in the pursuit of reestablishing long term sustainability, life sciences organizations are just beginning to embrace true digital transformation. The goal is to deploy a more holistic strategy that supports a much broader organizational approach to transformation than the current incremental focus on near term technological innovation, operational efficiency and the externalization of non-core competencies common in industry transformation efforts today.
The following is a guest post by Thomas Bentz, who is part of the Brand Marketing team at Dassault Systèmes. To download the solution brief for Designed to Cure, click here. The drug development process has become increasingly expensive and focused on improved returns on investment. With average development taking […]
The following is a guest post by Thomas Bentz, who is part of the Brand Marketing team at Dassault Systèmes. To download the solution brief for One Lab ISE, click here. In today’s competitive environment, Life Sciences organizations need to optimize lab operations by improving efficiency while maximizing quality and […]
Conventional wisdom says that Americans get more than enough protein in our diets. In fact, we’re often told that we consume too much protein. Recent studies, however, have shown us otherwise. Evidence suggests that we need to increase our protein intake for optimal health. The benefits provided by greater protein intake include improved muscle function and mobility as well as potentially preventing and treating chronic diseases. In addition to the possible benefits of boosting heart and digestive health, more protein also promotes satiety, which aids in weight maintenance. Could adding more protein to our diet help our ongoing battle against obesity?
A big change is coming to store shelves. Late last year, President Obama signed a bill that bans the sale and distribution of products containing plastic microbeads. The law is part of an ongoing effort to protect our nation’s waterways. For the purpose of the new law, a microbead is defined as a plastic particle that’s less than 5 millimeters in diameter. Microbeads, however, can be found in all sorts of personal care products, ranging from toothpaste to exfoliating scrubs. They’re meant to cleanse and due to their miniscule size, wash down the drain.